Europe Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories

Europe Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)   

The Europe cervical cancer diagnostic testing market is expected to grow from US$ 1,368.86 million in 2021 to US$ 1,881.38 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2021 to 2028. Cancer has emerged as a leading cause of death across the region. The market under consideration has shown significant expansion, linked to the rising frequency of cervical cancer among women across the region. Cervical cancer mortality rates are greater in poorer nations due to the late diagnosis of the disease. The market is predicted to rise due to the increasing acceptance of cervical cancer diagnostic tests for the early detection of cervical cancer. The rising prevalence of cervical cancer has created a burden on the healthcare systems across the region. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to lead to an even greater burden of cancer in the region in the coming years. Therefore, it is essential to control and prevent the increasing number of cancers across the region. Various governments have initiated programs and initiatives to increase cancer treatment and preventive measures. For instance, in 2017, World Health Assembly has approved the Resolution Cancer (WHA70.12), an integrated approach to prevent and control cancer. The program has been appealing the WHO and various European governments to accelerate their efforts to achieve the targets that are specified in the Global Action Plan (2013-2020) for the prevention and control of noncommunicable diseases (NCDs) and in the 2030 UN Agenda for Sustainable Development to reduce early deaths from cancer. In addition, various private organizations have joined the action plans to prevent the increasing burden of cancer, creating a demand for better preventive measures against the disease. Thus, the growing prevalence of cervical cancer has accelerated the need for new and efficient therapeutic approaches, such as neoantigens, which is boosting the growth of the Europe market.

COVID-19 has highly affected Europe, especially the UK. The pandemic has caused a decline in various medical procedures, such as screening, follow-up, HPV triage tests, invasive diagnostic, and treatment of cervix-related indications. There is a need to create awareness among women about early cervical cancer screening advantages. The unwillingness of patients to take the test is expected to affect the market in the region over the next few years. However, Hologic Inc. launched Genius Digital Diagnostics System in November 2021, which is now commercially available in Europe. Thus, such active involvement of the international market players in the regional markets is expected to positively impact the region's market in the near future.

Based on service provider, The diagnostics and research laboratories segment led the Europe cervical cancer diagnostic testing market in 2020. Diagnostic laboratories and research laboratories are among the primary service providers for Cervical Cancer Diagnostic Testing. It has well-established facilities as per the regulatory requirements. The laboratories use every possible diagnostic product and method to test the samples provided by the various sampling methods, such as biopsies and blood samples. Samples collected from the patients are analyzed and studied using different instruments, reagents, techniques, and technologies. These samples may be further utilized to study the indications or develop the test processes and technologies. Additional lab services provide hospitals, clinics, at-home care, and others to test their in-house test samples. The increasing prevalence of chronic diseases, such as cancer and infectious diseases, outsourcing diagnostics testing activities by individual researchers is among the factors supporting the segment growth during the forecast period.

The overall size of the Europe cervical cancer diagnostic testing market has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast for the market concerning all the segments of the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data and gain more analytical insights into the topic. Participants who typically participate in such processes include industry experts, such as VPs, business development managers, market intelligence managers, national sales managers, and external consultants, such as valuation experts, research analysts, and key opinion leaders specializing in the market. Abbott; BD; Cooper Companies, Inc.; DYSIS Medical Inc; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Inc. are among a few players in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe cervical cancer diagnostic testing market.   
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe cervical cancer diagnostic testing market, thereby allowing players across the value chain to develop effective long-term strategies 
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the cervical cancer diagnostic testing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution